Inflation And COVID Putting Pressure On Europe’s Paracetamol Supply Chain
Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain, according to an investigation by HBW Insight. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.
You may also be interested in...
HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.
Following a review of a recent study warning against paracetamol use by pregnant women, the heads of European Union medicines agencies have decided that the evidence was "inconclusive" and therefore no product patient information updates are necessary.
High sodium content in effervescent paracetamol could increase risk of cardiovascular disease and mortality in people with and without hypertension, says a recently published study. The authors of the study recommend that the safety profile of such products be reviewed.